ADLM 2024

The Association for Diagnostics and Laboratory Medicine (ADLM, formerly AACC) 2024 annual meeting in Chicago was well-attended by around 18,000 attendees, including leaders in molecular diagnostics, new point-of-care testing technology, clinical chemistry, and other areas in laboratory medicine. This was Co-Dx's 4^th year hosting a booth and delivering an update presentation, and with each our presence has grown more prominent. 2024 was our first year submitting a poster abstract, which we are pleased to say was accepted and recognized by the conference organizers.

The Company presentation this year discussed how innovations in the Co-Dx™ PCR platform are advancing POC and OTC diagnostics, especially as those advancements relate to closing the global accessibility gap between high-quality diagnostics and the people who need them.

Co-Dx ADLM 2024 Booth

The Co-Dx booth is always the focal point of our conference attendance. Designed to showcase our various Co-Primers®-based PCR molecular solutions, and to especially showcase the Co-Dx PCR Pro™ and accompanying tests, our booth provides visitors with the opportunity to get to know Co-Dx if it's the first time visiting. It's also equipped with seating areas for those contacts with whom a deeper dive is more appropriate, as we discuss strategy, potential upcoming milestones, and opportunities for working together to advance the Co-Dx mission of increasing access to gold-standard PCR diagnostics worldwide.

Prominently featured in the center of the booth is an eye-catching LED screen displaying a carousel of our current and future PCR solutions. This is also where our in-booth presentations take place, as often as twice per day, giving Co-Dx representatives greater opportunities to draw in traffic. This year the presentations included raffle giveaways for those lucky enough to attend.

Traffic is always high in the Co-Dx booth, from potential customers, media representatives, prospective collaborators, and even fellow point-of-care testing device manufacturers. It's not uncommon (and always rewarding) to introduce the company and its vision to someone learning about us for the first time, then the next day see them return with their colleagues in tow and be asked to run through the innovations of the Co-Dx PCR testing platform so their colleagues can see it for themselves.

Scientific Poster: COVID-19 on the PCR Pro: a consumer-friendly PCR test

Daniel Garey (center) receives recognition for poster presentation

This year was our first to submit an abstract to ADLM for a scientific poster and we were pleased to see it accepted. Titled COVID-19 on the PCR Pro: a consumer-friendly PCR test, the poster was presented by Co-Dx Analytical Team Lead Dan Garey. It contained a description of the workflow process for the Co-Dx PCR COVID-19 Test on the Co-Dx PCR Pro, including the sample collection and operational instructions, and a description of how the tests are "called," or confirmed to be positive or negative for the target pathogen, using an automatic calling algorithm and displayed on the platform's mobile app. The poster also detailed the results of two analytical studies, one performed internally by Co-Dx and the other externally by PATH. The respective SARS-CoV-2 Limit of Detection results were 2,100 viral copies per anterior nasal swab, and 408 viral copies per test.

As gratifying as it was to be accepted by the conference organizer to present this poster in the first place, it was even more exciting to learn that the poster was 1 of only 4 diagnostics posters selected out of the hundreds presented to deliver an in-depth e-presentation on Wednesday July 31 at the conference. Co-Dx sees this recognition as a validation of the future value of the Co-Dx PCR Pro and Co-Dx PCR COVID-19 test for point-of-care and at-home testing.

Advancing POC/OTC diagnostics: Innovations in Test Development for the New Co-Dx PCR Platform

On Tuesday, July 30, Co-Dx CEO Dwight Egan and Executive VP of Business Development Joseph Featherstone addressed how the company is taking an advanced position in the worldwide initiative to end tuberculosis (TB) by 2030 in a special company presentation.

The presentation summarized the milestones to date and discussed the potential future role of the Co-Dx PCR platform in closing the global diagnostics gap for an array of potential indications, especially point-of-care testing for TB. Developed by world-renowned engineers and scientists, the Co-Dx PCR Pro instrument, software and tests comprise the platform for the digital age, combining patented Co-Primers chemistry and elegant engineering to make gold-standard PCR diagnostics available to anyone, anywhere.

Clinical samples from tuberculosis patients have already been run in TB test cups on the Co-Dx PCR Pro instrument and presentation included Company representatives sharing their confidence in the quality of the results seen so far.

The potential impact of the platform was illustrated by this slide:

The platform's first FDA 510(k) application, for a COVID-19 test, was submitted in mid-June. The tests in the pipeline are expected to meet the diverse needs of a global market.

The Co-Dx PCR Pro, along with associated mobile app software and diagnostic tests, requires regulatory approval for diagnostic use, is subject to U.S. FDA and local regulatory marketing authorization status and is currently not for sale.